Effect of Vancomycin Administration Method on Achieving and Maintaining Its Serum Concentrations In Intensive Care Patients

Sokolova, Vera; Sabelnikovs, Olegs

doi:10.2478/chilat-2014-0004

Abstract

Introduction. Vancomycin may be administered by bolus injections (BI) and continuous infusion (CI). Data on BI and CI clinical effectiveness and correlation with mortality, survival and renal injury is variable.

Aim of the study. The aim of the study was to compare the use of vancomycin continuous infusion and bolus administration in intensive care.

Materials and methods. Retrospective analysis of 46 ICU patients (23 patients received vancomycin CI and 23 - BI) was undertaken to compare efficacy and effect on mortality and morbidity of these two administration methods.

Results. The study revealed association of CI administration with more effective (15 - 25 mg/L) serum vancomycin trough concentration maintenance (31.2% vs 25.6% of treatment time, p=0.011) as well as with reduced incidence of subtherapeutic vancomycin levels (34.3% vs 37.2% of treatment time, p=0.015). We also observed better survival times using CI mode.

Conclusions. CI appears to be beneficial in terms of better maintenance of target VSTC and better patient survival. However, its use compared to bolus administration has no statistically significant impact on overall mortality and incidence of nephrotoxicity.

References

1. Cataldo MA et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections, systematic review and meta-analysis. // J Antimicrob Chemother, 2012; 67(1):17-24.10.1093/jac/dkr44222028203
Search in Google Scholar
2. Devabhakthuni S. Antibiotic Pharmacokinetic Monitoring. // Published 2011. Retrieved on May 22, 2013 from www.ashp.org/DocLibrary/MemberCenter/NPF/2011Pearls/Antibiotic-Pharmacokinetic-Monitoring.aspx
Search in Google Scholar
3. Di Filippo A et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. // Chemotherapy, 1998; 44(1):63-68.10.1159/0000070929444411
Search in Google Scholar
4. Hidayat LK et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections, efficacy and toxicity. // Arch Intern Med, 2006; 166:2138-2144.10.1001/archinte.166.19.213817060545
Search in Google Scholar
5. Ibrahim NS et al. Time to Achieving Target Concentration of Vancomycin, Intermittent Infusion versus Continuous Infusion of Vancomycin in Intensive Care Unit. // Published 2011. Retrieved on March 22, 2013 from http://www.kck.usm.my/husm/pharmacy/images/penerbitan
Search in Google Scholar
6. Jeffres MN et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillinresistant Staphylococcus aureus pneumonia. // Clin Ther, 2007; 29:1107-1115.10.1016/j.clinthera.2007.06.01417692725
Search in Google Scholar
7. Law Min C, Bourne R. Continuous Vancomycin Infusion Guidelines in Critical Care. // Sheffield Teaching Hospitals NHS Foundation Trust Guidelines, 2012.
Search in Google Scholar
8. Lodise TP et al. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. // Antimicrob Agents Chemotherapy, 2008; 52:1330-1336.10.1128/AAC.01602-07229253618227177
Search in Google Scholar
9. Nguyen M et al. Nephrotoxicity associated with high dose vs standard dose vancomycin therapy. // In: 47th Interscience Conference on Antimicrob Agents Chemotherapy. 2007; Chicago, IL, September 2007.
Search in Google Scholar
10. Pauly DJ et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. // Pharmacotherapy, 1990; 10:378-382.
Search in Google Scholar
11. Pea F et al. Prospectively validated dosing nomograms for maximizing pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. // Antimicrob Agents Chemotherapy, 2009; 53(5):1863-1867.10.1128/AAC.01149-08268151519223642
Search in Google Scholar
12. Rello J et al. Pneumonia caused by oxacillinresistant Staphylococcus aureus treated with glycopeptides. // Crit Care Med, 2005; 33(9):1983-1987.10.1097/01.CCM.0000178180.61305.1D
Search in Google Scholar
13. Roberts JA et al. Better outcomes through continuous infusion of time dependent antibiotics to critically ill patients? // Curr Opin Crit Care, 2008; 14:390-396.
Search in Google Scholar
14. Roberts JA, Lipman J. Antibacterial dosing in intensive care, pharmacokinetics, degree of disease and pharmacodynamics of sepsis. // Clin Pharmacokinet, 2006; 45:755-773.10.2165/00003088-200645080-0000116884316
Search in Google Scholar
15. Rybak MJ et al. Vancomycin Therapeutic Guidelines, A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. // Clin Infect Dis, 2009; 49:325-327.10.1086/60087719569969
Search in Google Scholar
16. Rybak MJ, Lomaestro B. Therapeutic monitoring of vancomycin in adult patients, A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. // AJHP, 2009; 66:82 - 98.
Search in Google Scholar
17. Rybak MJ et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. // J Antimicrob Chemother, 1990; 25:679-687.10.1093/jac/25.4.6792351627
Search in Google Scholar
18. Vuagnat A et al. High dose vancomycin for osteomyelitis, continuous vs intermittent infusion. // J Clin Pharm Ther, 2004; 29(4):351-357.10.1111/j.1365-2710.2004.00572.x15271102
Search in Google Scholar
19. Wysocki M et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections, prospective multicenter randomized study. // Antimicrob Agents Chemotherapy, 2001; 45(9):2460-2467.10.1128/AAC.45.9.2460-2467.20019067811502515
Search in Google Scholar

Effect of Vancomycin Administration Method on Achieving and Maintaining Its Serum Concentrations In Intensive Care Patients

Abstract

Paradigm

My account